Menu
Washingtoner
  • Home
  • Health
  • Books
  • Artificial Intelligence
  • Business
  • Construction
  • Music
  • Longevity
  • Technology
Washingtoner

Juventix Regenerative Medical PRP Highlighted in University-Published Research Study
Washingtoner/10277008

Trending...
  • Spokane: Second-Alarm Brush Fire Contained at People's Park
  • As the FCC Router Ban Creates a National Supply Chain Crisis, Haawke Hash Offers the Infrastructure
  • Tacoma City Council Expresses Opposition to Initiative Measure No. IL26-001 and Initiative Measure No. IL26-638
Laboratory Testing for Product Validation BSR Labs Juventix PRP Study Table Juventix Packaging With Tubes Juventix Regenerative Medical, LLC
TAMPA, Fla. - Washingtoner -- Juventix Regenerative Medical, a leader in regenerative medicine solutions, proudly announces that its Platelet-Rich Plasma (PRP) technology has been featured in a groundbreaking university-published research study. The study, titled "Platelet-Rich Plasma for Rheumatoid Arthritis: A Case Series", published in the peer-reviewed journal Cureus, underscores the efficacy of Juventix PRP in managing rheumatoid arthritis, showcasing its transformative potential in clinical applications.

The study explores the use of PRP to address inflammation and improve outcomes in rheumatoid arthritis patients, with findings demonstrating measurable benefits attributed to Juventix PRP's advanced process. The research highlights the role of PRP in promoting tissue repair and reducing joint pain, offering a promising non-surgical alternative for patients seeking regenerative therapies.

Scientific Validation Backed by Laboratory Studies
Juventix PRP's inclusion in this research aligns with findings from extensive laboratory evaluations conducted by BioSciences Research Associates (2020) and Biofyl Scientific Research (2023). Key results include:
  • 84% platelet recovery, significantly enhancing platelet-derived growth factor (PDGF) concentrations.
  • 10x increase in PDGF levels, with treated PRP reaching 10,844 pg/mL compared to 1,536 pg/mL in untreated samples.
  • Minimal contamination of red and white blood cells, ensuring safety and reducing inflammatory risks.
  • Optimized pH of 7.5, creating an ideal environment for platelet activation and growth factor release.
  • Innovative activation methods, including photoactivation and bio-incubation, transforming PRP into PRF for versatile clinical applications.
"The inclusion of Juventix PRP in a peer-reviewed study underscores our commitment to delivering scientifically validated, high-quality regenerative solutions," said Lance Liberti, CEO of Juventix Regenerative Medical. "Our focus on innovation ensures practitioners can trust Juventix PRP for consistent, superior patient outcomes."

More on Washingtoner
  • Working Musicians Academy Partners with Black Dog Music Partners to Give Musicians Independent, Income-Producing Careers
  • Spokane: Community Resources Available to Those Impacted by Fires
  • Spokane Police Urge Public to Stay Out of Fire Evacuation Areas
  • Spokane launches wildfire relief fund
  • VFW Mobilizes to Support Members and Communities Affected by Eastern Washington Wildfires

Special Offer for Medical Practitioners
To introduce clinicians to its cutting-edge PRP systems, Juventix is offering a sample PRP kit for only $20. This limited-time opportunity enables practitioners to experience the proven quality of Juventix PRP firsthand.
• Email: hello@juventix.com with the subject line "SAMPLE"
• Visit: https://juventix.com/sample-page/

About Juventix Regenerative Medical, LLC
Founded in 2017 by Lance Liberti, Juventix Regenerative Medical has been a pioneer in non-surgical regenerative solutions, including FDA-cleared PRP kits. The company offers comprehensive products such as centrifuges, LED activators, and bio-incubators to support superior PRP preparation. Juventix also collaborates with prestigious organizations, including the University of South Florida (USF) Health Center for Advanced Medical Learning and Simulation (CAMLS), to host advanced clinical training symposiums.

For more information, visit www.Juventix.com or contact:
📞 (866) 693-4777

More on Washingtoner
  • Omnitronics launches Ecosystem Health Dashboard to enable proactive monitoring across dispatch environments
  • New Research Identifies "The Great Junk Transfer": 49% of Americans Would Rather Inherit Nothing Than Sort Through a Relative's Belongings
  • Minus K Technology launches it Educational Giveaway for Universities and Colleges in the USA
  • UK Financial Ltd Verifies Maya Preferred PRA Circulating Supply, Proving Its Eight-Year Promise of Under 1M Tokens After Chainlink Labs Agreement
  • Anamorphic 3D Only Works on Fixed Screens. Loud! OOH Put It on a Moving Ad Van for Flood Re

✉️ Email:
hello@juventix.com
Restore, Revive, Regenerate – Juventix Regenerative Medical.

Media Contact
Lance Liberti
***@juventix.com
866-693-4777


Source: Juventix Regenerative Medical, LLC

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • $620 Million in Recent Government Contract Awards with More Than $1.2 Billion in Annualized Revenue: Circle8 Group (N A S D A Q: CIRC)
  • Lewis County Hydrogen Alliance Launches Phase 1 Work to Turn Forest Residuals into Fuel-Grade Hydrogen and Dispatchable Clean Power
  • Next Gen Fibre Selects netElastic vBNG and CGNAT to Fuel Rapid Nationwide Expansion and Eliminate Network Bottlenecks
  • Boston Industrial Solutions, Inc. Introduces SAP-G70 Primer for bonding silicone to silicone and other materials
  • Tacoma: Capital Ready: Preparing Businesses for Growth in Public Contracting Workshop on August 26, 2026
  • Final Week for Spokane Falls Boulevard Survey
  • 'Reflections: Enlightening Insights Into the Divine Mystery' — The Latest Book by Philosopher Steven Colborne
  • Scott G. Hoy of Hoy Law Earns 11th Consecutive Super Lawyers Selection
  • Spokane: SPD is Seeking Assistance in Locating Missing Adult Male
  • Tacoma: Hylebos Bridge Closed to Vehicular Traffic
  • L2 Aviation Selected for U.S. Air Force KC-46 CASPER Multiple Award Contract
  • Leeds Billboard Campaign Drives 188% Traffic Uplift as AI Enquiries Rise 266% for Loud! OOH
  • Sister Files Lawsuit Against Georgia Funeral Home for Alleged Mishandling of Brother's Remains
  • KeysCaribbean Resorts Offer Savings On Summer Vacations Now Through Aug. 31
  • Crossroads4Hope Announces The Lipschutz Women's Fund
  • AI, Drones, Defense & Explosive Growth: Why ZenaTech Is Emerging as One of the Most Compelling Technology Growth Stories (N A S D A Q: ZENA)
  • The truth behind mylifesflow.com and the poet, Taryn "My Life's Flow" Robinson
  • 91 Per Cent of Enterprises Will Increase AI Spending. Most Can't See the Cost — or the Risk!
  • New ProEssentials v11: Native WinUI Charting Library, 100M Points in 15ms, Following Microsoft's Vision for True Native Swap-Chain Rendering
  • Salestrics Releases Version 2.0 to Unify CRM, Business Email, and Operations on a Single Customer Graph
_catLbl0 _catLbl1

Popular on Washingtoner

  • Martin A. Sumichrast Joins Hawkeye Systems, Inc. as Chairman of the Board
  • Qscription Technologies Appoints Radiology Industry Veteran Elliot Silverman to Advisory Board
  • Spokane: Camp Sekani Update 7/9/26
  • Postmortem Pathology Expands Access to Private Autopsy Services in Las Vegas
  • Homicide Investigation – 1000 block of South Tacoma Way
  • MD Marine Electric Announces Rebranding as MD Electric Group
  • Kolbus Introduces the Next Step in Casemaking Efficiency
  • Sara Abbas Receives "Eniochos" Charioteer Award at 2026 Who is Who International Awards
  • Michigan's Plane Crash Data Points Away from Big Airports
  • Rising star Hip-Hop and R&B Force Della Drops Highly Anticipated New Single, "Throw It"

Similar on Washingtoner

  • Haven Treatment Center Achieves IMD Certification, Expanding Access to Residential Care
  • Minus K Technology launches it Educational Giveaway for Universities and Colleges in the USA
  • FDA Food Recall Notices After Outbreak Linked to 98 Hospitalizations: Practical Tips for Safer Grocery Shopping
  • Boston Industrial Solutions, Inc. Introduces SAP-G70 Primer for bonding silicone to silicone and other materials
  • Crossroads4Hope Announces The Lipschutz Women's Fund
  • Aderra Opens in Magnolia, Texas, Offering a New Model for 62+ Homeownership
  • Are "Buck Teeth" Hereditary? Spokane Valley Dentist Explains Children's Smile Development
  • James Richey, CEO of JouleFit, to Be Featured on the July Edition of the Longevity Leaders Project
  • DARPA Selects NRx Pharmaceuticals Defense Subsidiary for Contract Negotiations on FDA-Authorized SPARC-TMS Clinical Trial Advancing Mental Health Care
  • U.N. Committee Reiterates Forced Psychiatric Detention a Human Rights Violation; CCHR Calls on the U.S. to Implement Protections
Copyright © 2026 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute